Independent Portfolio Consultants’s Genomic Health, Inc. GHDX Stock Holding History

Independent Portfolio Consultants’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$519K	Sell	15,951 -1,904	-11%	-$60.3K	0.22%	158
2017 Q1	$562K	Buy	17,855 +625	+4%	+$18.5K	0.19%	185
2016 Q4	$506K	Sell	17,230 -185	-1%	-$5.64K	0.17%	214
2016 Q3	$504K	Sell	17,415 -180	-1%	-$5.01K	0.16%	227
2016 Q2	$456K	Buy	17,595 +6,210	+55%	+$165K	0.14%	229
2016 Q1	$282K	Buy	11,385 +95	+0.8%	+$2.61K	0.08%	295
2015 Q4	$397K	Sell	11,290 -10,475	-48%	-$281K	0.12%	236
2015 Q3	$461K	Buy	21,765 +3,275	+18%	+$84.4K	0.1%	257
2015 Q2	$514K	Buy	18,490 +4,335	+31%	+$122K	0.1%	249
2015 Q1	$432K	Sell	14,155 -610	-4%	-$19.4K	0.09%	257
2014 Q4	$472K	Buy	14,765 +8,230	+126%	+$268K	0.1%	255
2014 Q3	$185K	Buy	6,535 +220	+3%	+$6.13K	0.05%	477
2014 Q2	$173K	Buy	+6,315	New	+$168K	0.05%	462

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Independent Portfolio Consultants's GHDX Position: Q2 2017 in Review

Independent Portfolio Consultants reduced its Genomic Health, Inc. (GHDX) stake by 11% in Q2 2017, selling an estimated $60.3K and leaving 15,951 shares worth $519K. The position accounts for 0.22% of the portfolio, ranked #158.

Independent Portfolio Consultants first reported a position in GHDX in Q2 2014 and has held it in 13 quarters since. The position peaked at $562K in Q1 2017. 124 funds tracked by Wall St. Rank hold GHDX as of Q2 2017.

Independent Portfolio Consultants held 15,951 shares of Genomic Health, Inc. worth $519K as of Q2 2017.
Independent Portfolio Consultants sold 1,904 Genomic Health, Inc. shares in Q2 2017, an estimated $60.3K.
Genomic Health, Inc. made up 0.22% of Independent Portfolio Consultants's portfolio in Q2 2017, its #158 holding.
Independent Portfolio Consultants first reported a position in Genomic Health, Inc. in Q2 2014 and has held it in 13 quarters since.
Independent Portfolio Consultants's Genomic Health, Inc. position peaked at $562K in Q1 2017.
124 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q2 2017.

Based on Independent Portfolio Consultants's 13F filing for Q2 2017, filed 6 Jul 2017.